Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.

Authors:
  • JOJames O'Reilly
    James O'Reilly
  • ADAmy Dalal
    Amy Dalal

  • 1 January 2003
    • journal article
    • other
Abstract
Professor O'Reilly's study of recent drug review legislation applies a historical and holistic view of promotion practices for unapproved uses of prescription drugs. He faults Congress for moving public health protections away from a strictly protective mode and toward assistance to drug marketers. He argues that the adverse health consequences of "off-label" promotion of drugs are not well understood, and that the 1997 amendments deserved the public health interest while expanding pharmaceutical company profits.